U.S. Banks Stock News

If you are wondering whether NIO at about US$4.89 is a bargain or a value trap, you are not alone. This breakdown is here to unpack that question in more detail. The share price has moved 8.2% over the last week and 5.4% over the last 30 days, while the year to date return is a 4.9% decline and the 1 year return sits at 12.9%. This compares with much weaker 3 year and 5 year returns of 52.6% and 91.8% declines respectively. Recent coverage of NIO has focused on its position in the electric...

Why Klarna Group is on investors’ radar Klarna Group (KLAR) has drawn attention after recent trading, with the share price at US$20.37 and short term returns under pressure over the past week, month, and past 3 months. See our latest analysis for Klarna Group. For context, Klarna Group’s recent weakness has been building for a while, with a 1-day share price return of 0.73% decline, a 30-day share price return of 35.23% decline, and a year to date share price return of 28.70% decline. This...

If you are wondering whether Jumia Technologies is still attractively priced after its recent volatility, you are not alone. This article will walk through what the current market price might be implying. The stock last closed at US$12.27, with returns of 195.7% over 1 year and 225.5% over 3 years, alongside shorter term moves of a 0.7% decline over 7 days, a 14.0% decline over 30 days, and a 4.4% decline year to date. These mixed returns, strong over several years but weaker in the near...

PowerFleet (AIOT) has just posted its latest numbers, with Q2 2026 revenue at US$111.7 million and a basic EPS loss of US$0.03, setting the stage for how you read the new Q3 2026 update. Over recent periods the company has seen revenue move from US$75.4 million and an EPS loss of US$0.21 in Q1 2025 to US$106.4 million with an EPS loss of US$0.11 in Q3 2025, then to US$103.6 million and an EPS loss of US$0.09 in Q4 2025, and US$104.1 million with an EPS loss of US$0.08 in Q1 2026. With the...

Why Maze Therapeutics (MAZE) Is On Investors’ Radar Maze Therapeutics (MAZE) has drawn fresh attention after recent trading, with the stock closing at $47.71 and showing strong trailing returns over the past year. This performance has prompted investors to reassess its clinical stage profile. See our latest analysis for Maze Therapeutics. The recent 5.95% 1 day share price return, on top of a 47.89% 90 day share price return and a very large 1 year total shareholder return of about 7x,...

Motorcar Parts of America (MPAA) has put out its latest quarterly scorecard, with Q2 2026 revenue at US$221.47 million and basic EPS of a US$0.11 loss, alongside trailing twelve month revenue of US$789.12 million and basic EPS of US$0.13. Over the past few reported periods, the company has seen revenue move from US$169.89 million in Q1 2025 to US$208.19 million in Q2 2025, US$186.18 million in Q3 2025, US$193.11 million in Q4 2025, US$188.36 million in Q1 2026, and US$221.47 million in Q2...

Venture Global overview after recent price moves Venture Global (VG) has drawn attention after a recent share price move, with the stock closing at US$10.17 and showing mixed return patterns across the past week, month and past 3 months. See our latest analysis for Venture Global. Recent moves sit on top of a much bumpier year, with a year to date share price return of 44.46% and a 1 year total shareholder return decline of 40.50%, suggesting recent momentum has not yet fully repaired earlier...

Hexcel’s recent performance and what it could mean for investors Hexcel (HXL) has attracted fresh attention after a strong past 3 months, with the stock showing a 25.03% total return and a 32.49% total return over the past year. See our latest analysis for Hexcel. At a share price of $86.06, Hexcel’s recent 7 day and 90 day share price returns of 5.48% and 25.03% sit alongside a 32.49% 1 year total shareholder return. This suggests momentum has been building rather than fading. If Hexcel’s...

IQVIA Holdings reported fourth-quarter 2025 sales of US$4,364 million and full-year sales of US$16,310 million, alongside issuing 2026 revenue guidance of US$17,150 million to US$17,350 million that factors in acquisition and foreign-exchange benefits. Recent moves, including a long-term Data-as-a-Service collaboration with Boehringer Ingelheim and ongoing share repurchases under a multi-year program, underline IQVIA’s push to deepen its role in data-driven healthcare decision-making. We’ll...

EQT Corporation's Board of Directors has declared a quarterly cash dividend. The dividend decision reflects the company's ongoing commitment to returning cash to shareholders. The announcement arrives as EQT (NYSE:EQT) trades around $56.13 per share. EQT, trading at about $56.13, has attracted attention with multi year returns that are very large, including a 90.5% return over 3 years and a 238.3% return over 5 years. In the shorter term, the stock shows a 9.9% return over the past 30 days...

Why Clorox (CLX) is back on many investors’ radar Clorox (CLX) has caught fresh attention after recent trading, with the stock now around $119.59 and showing positive returns over the past month and past 3 months. See our latest analysis for Clorox. Recent trading has added to that momentum, with a 30 day share price return of 12.62% and a 90 day share price return of 13.86%, even though the 1 year total shareholder return is still a 15.39% decline. This mix of shorter term strength and...

For investors wondering whether Intel at US$50.24 is still reasonably priced or if most of the easy gains are already behind it, this article walks through what the current numbers are really saying about the stock. Over the short term, Intel has returned 2.9% over the last 7 days and 10.3% over the last 30 days. Its year to date return is 27.6% and its 1-year return is 154.1%, compared to 80.3% over 3 years and a 10.6% decline over 5 years. These mixed return figures sit against a backdrop...

Why Graham Holdings (GHC) Is On Investors’ Radar Today Graham Holdings (GHC) has drawn attention after recent share price moves, with the stock closing at $1,118.60. That puts fresh focus on how its diversified operations and current return profile fit into long term portfolios. See our latest analysis for Graham Holdings. While the latest 3.42% one day share price decline and softer 7 day and 30 day share price returns may hint at cooling short term momentum, Graham Holdings still shows...

Sohu.com (SOHU) just posted its FY 2025 third quarter numbers, with revenue of US$180.2 million, basic EPS of US$0.32 and net income excluding extra items of US$8.7 million setting the tone for the latest update. The company has seen revenue move from US$151.9 million in Q3 2024 to US$180.2 million in Q3 2025, while basic EPS shifted from a loss of US$0.52 to a profit of US$0.32. This gives investors a cleaner read on how margins are shaping up after a volatile run of results. See our full...

In early February 2026, European Union competition regulators formally charged Meta Platforms with breaching antitrust rules by excluding rival artificial intelligence assistants from its WhatsApp messaging service, and signaled they may impose interim measures to prevent what they view as serious and irreparable harm to competition. The case puts WhatsApp’s Business API at the center of a broader fight over how much control a dominant messaging platform should have over access for...

Cleveland Cliffs (CLF) just posted its FY 2025 numbers with Q3 revenue of US$4.7b and a basic EPS loss of US$0.50, alongside trailing twelve month revenue of US$18.6b and a basic EPS loss of US$3.40. Over recent quarters the company has seen revenue move between US$4.3b and US$5.2b while basic EPS has ranged from a small loss of roughly US$0.00 to a loss of US$1.00 per quarter, setting a mixed backdrop for how you read this latest print. With the shares at US$12.31, investors are likely to...

In early February 2026, Pfizer reported mixed 2025 financial results, reaffirmed 2026 revenue guidance, highlighted progress in its GLP-1 obesity pipeline, secured FDA Priority Review to expand HYMPAVZI’s hemophilia indication, and joined the TrumpRx drug pricing platform with discounted access to more than 30 medicines. Together, these developments underscore how Pfizer is trying to offset patent expiries and waning COVID-19 revenues by building new specialty and obesity franchises while...

Dynatrace (DT) just posted its Q3 2026 scorecard with recent quarterly revenue running at about $493.8 million and Basic EPS of roughly $0.19, set against a trailing 12 month picture that includes Basic EPS of $1.69 and revenue of about $1.9 billion, plus earnings growth in the dataset of 210.1% over the past year. The company has seen revenue move from $399.2 million in Q1 2025 to $493.8 million in Q2 2026 and quarterly Basic EPS shift from $0.13 to $0.19 over the same period. Year long...

Waters (WAT) FY 2025 earnings snapshot Waters (WAT) reported Q3 FY 2025 revenue of US$799.9 million and basic EPS of US$2.50, with trailing 12 month EPS of US$10.91 on revenue of about US$3.1 billion. The company’s quarterly revenue rose from US$708.5 million in Q2 2024 to US$771.3 million in Q2 2025, and then to US$799.9 million in Q3 2025. Over the same periods, basic EPS moved from US$2.41 to US$2.47 and then to US$2.50, highlighting a story focused on consistent earnings and resilient...

This article examines whether Medline, at around US$47.37, is trading at fair value or something more compelling, and explores what the current price might be indicating. Over shorter time frames, the stock has returned 5.2% over the last week, 16.9% over the last 30 days and 16.6% year to date. These moves may have drawn the attention of investors who follow momentum and shifts in risk sentiment. Recent news about Medline has focused on its position in the healthcare space and how investors...

Why Brookfield Business Partners Stock Is Back on Investors’ Radar Brookfield Business Partners (NYSE:BBU) just paired its 2025 earnings release with a fresh share buyback update and an affirmed dividend plan tied to its upcoming corporate reorganization, drawing fresh attention from income focused investors. See our latest analysis for Brookfield Business Partners. The confirmed dividend, completed 1% share buyback and narrowing annual net loss have arrived alongside stronger trading...

Roblox (NYSE:RBLX) reported strong fourth quarter results, highlighting solid bookings and active user metrics. The company introduced facial age estimation and more than 145 new safety initiatives across its platform. Management emphasized a focus on leading online safety standards for both younger users and a growing adult audience. Roblox runs a global 3D social and gaming platform where users create, share, and play content built by the community. The latest safety updates sit alongside...

PVH Corp. recently announced a collaboration with OpenAI to co-create custom AI tools across Calvin Klein, Tommy Hilfiger and its broader operating model, and earlier affirmed a quarterly cash dividend of US$0.0375 per share payable on March 25, 2026 to shareholders of record on March 4, 2026. The AI partnership is designed to embed advanced analytics into product design, demand planning, inventory optimization and consumer engagement, potentially reshaping how PVH runs its core fashion and...

In early February 2026, Exact Sciences reported that its Oncotype DX Breast Recurrence Score test has now guided treatment decisions for more than two million early-stage HR+, HER2- breast cancer patients worldwide, supported by over two decades of clinical evidence and broad global adoption. The company highlighted that Oncotype DX remains the only genomic assay proven to be both prognostic and predictive for chemotherapy benefit, with published models suggesting meaningful lifetime cost...